Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial.

Eur J Heart Fail · 2023 · PMC10092840 · PMID 36181769

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

On the other hand, sacubitril/valsartan resulted in a borderline significant 17% reduction in new loop diuretic initiations and a small early net reduction in overall loop diuretic requirement.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.